Seeking men and women 18 years of age or older who have had a stroke caused by bleeding in their brain to help determine is a new drug called recombinant factor VIIa (rFVIIa) can improve outcomes compared to a placebo when added to the standard care provided after a stroke.
This study is being conducted to see if a medicine used to treat and prevent bleeding improves outcomes after a stroke caused by bleeding in the brain. The medicine is called Recombinant Factor VIIa (rFVIIa). Participants in this study will receive either the medicine or a placebo that contains no active medications.
What we're hoping for
To determine if treatment with Recombinant Factor VIIa (rFVIIa) works better than a placebo to improve participants outcome after a stroke
ClinicalTrials.gov Identifier: NCT03496883